Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chinese Health Authorities, Alarmed By Prospect Of 100 Million-plus Diabetics, Create Doctor Training Programs As Global Drug Outfits Step Up R&D

This article was originally published in PharmAsia News

Executive Summary

BEIJING - Alarmed by a 2010 study that showed China lies at the epicenter of an explosion in new diabetes cases, China's Ministry of Health is stepping up physician training courses and planning screening services across major cities, according to Chinese and Western scholars

You may also be interested in...



As Lilly Wades Through The Patent Cliff, It Sees Hope In Emerging Markets

Citi Investment Research says Lilly is the “best positioned” among U.S. pharma in China; here’s why.

Victoza Approved In China: Novo Nordisk Gears Up To Conquer China's Diabetes Market

SHANGHAI - Denmark's Novo Nordisk AS announced March 15 that its human glucagon-like peptide-1 (GLP-1) analogue Victoza (liraglutide) was granted regulatory approval from China's State FDA, and plans to launch the anti-diabetes drug in the second half of this year

Victoza Approved In China: Novo Nordisk Gears Up To Conquer China's Diabetes Market

SHANGHAI - Denmark's Novo Nordisk AS announced March 15 that its human glucagon-like peptide-1 (GLP-1) analogue Victoza (liraglutide) was granted regulatory approval from China's State FDA, and plans to launch the anti-diabetes drug in the second half of this year

Related Content

UsernamePublicRestriction

Register

OM009163

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel